1 published article · Updated continuously
7 trials tracked for Streptococcus pneumoniae: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 82 citations.
Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
The pneumococcal conjugate vaccine (GSK1024850A) demonstrates significant efficacy in preventing culture-confirmed invasive pneumococcal disease (IPD) caused by any of the 10 pneumococcal vaccine serotypes. In children starting vaccination within 7 months of life, a 3-dose primary course resulted in a person year rate of 0.000 compared to 0.564 in the control group (p<0.0001) [1, 3]. A 2-dose primary course also showed significant reduction in IPD rates, with 0.048 observed versus 0.564 in the control group (p=0.0009) [1, 3].
Clinical data regarding safety and immunogenicity for GSK1024850A indicate that the vaccine achieves seroprotection, with results showing 113 out of 360 subjects reaching anti-PRP levels above the 1.0 µg/mL cut-off 5. Safety profiles include recorded adverse events occurring within 7 days of vaccination 2 and specific counts of Grade 3 solicited local symptoms (ranging from 0 to 14) and general symptoms (ranging from 0 to 12) 4.
AI synthesis of 3 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
